Glenmark Pharmaceuticals 报告了更多与 COVID-19 大流行相关的法匹拉韦阳性数据
西方媒体会接受吗？
格伦马克
最近公布了其在印度法匹拉韦的上市后监测 (PMS) 研究中 503 名患者的中期数据。
这项研究始于 2020 年 7 月
目的是评估抗病毒药物在轻度至中度 COVID-19 患者中的安全性和有效性。
印度正在进行的第一项也是最大的上市后研究
涉及 Favipiravir 治疗轻度至中度 SARS-CoV-2 感染，共有 1083 名患者参加了前瞻性、开放标签、多中心、单臂研究
涉及 13 个政府和私人试验地点
孟买，
班加罗尔
海得拉巴，
纳西克，
那格浦尔
和特里凡得琅。
到目前为止，数据非常有希望，没有显示出新的安全信号或使用研究药物的担忧（目前在紧急情况下授权）
and known side effects such as
weakness,
gastritis,
diarrhea,
vomiting, etc.
which were found to be mild.Glenmark reports that
the time to fever resolution was reported on day 3, while two-thirds of the patients achieved clinical cure by day 7.
TrialSite emphasizes that
these antivirals are used in many nations yet in places such as North America and Europe, the press barely mentions the use of this now generic drug.
the drug
is authorized for use in India and several other countries including Russia.With a mean age of 40, the most common study age cohort was 30 to 45 years of age.
The study included 40% female and 60% male subjects.
The two most common comorbidities included hypertension and diabetes.
At baseline,
the study teams found fever present in all patients along with cough (84.6%), fatigue (55%) and new loss of taste (38.1%).